program, their frequency has been increasing by 0.3% per year over the last decade [2] . While OS occurs most frequently in patients between 5
years of age and early adulthood, incidence peaks again in the older ([65) populations and has been associated with pre-existing Paget's disease and prior radiation therapy [3] [4] [5] [6] [7] . Collectively, the metaphysis of the lower long bones, specifically the distal femur and proximal tibia, are the most commonly involved primary sites, with patients over 25 displaying a greater variety of bony locations [3] . Moreover, even in the subset of patients free of primary metastases, 40% will go on to eventually develop a secondary metastasis [12] ; in one study, survival rates of patients with nonmetastatic high-grade OS with subsequent metastases were 23% at 5 years and 0% at 4 years for pulmonary and bony metastases, respectively [24] .
In contrast to distant pulmonary and extrapulmonary metastases, skip lesions (also known as skip metastases or synchronous regional bone metastases) are local and yet potentially more serious metastatic complications. These small, anatomically isolated cancerous foci are distinct from the primary tumor and located either within the same bone or transarticular to it [25, 26] . Classically, they are associated with extensive metastatic dissemination, robust therapeutic resistance, and particularly poor prognoses 
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This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. Others have suggested an association between bone growth and incidence rates [75, [77] [78] [79] [80] , but the relative strength and importance of this relationship have been challenged [81] . Environmental factors that have been associated with increased risk of future OS development include exposure to radiation [6, 7] , teriparatide usage [82] , and consumption of fluorinated drinking water during childhood [83, 84] ; however, more recent studies have disputed the latter two relationships [85] [86] [87] [88] .
ETIOLOGY AND GENOMICS

DIAGNOSIS AND PATHOLOGY
Due to the complex nature of primary bone malignancies, diagnosis of OS is best accomplished via a comprehensive multidisciplinary approach [89] . Often, the first sign of potential bone malignancy is intermittent pain around the affected area with or without a palpable mass [90] . When involving areas around the knee joint, pain exacerbated by weight bearing may manifest as a limp; occasionally, patients will present with a recent bout of bone trauma [91] . As previously mentioned, any older adult with a history of Paget's disease has an increased risk of developing OS, most notably of the pelvis [92] , and this transformation is associated with a poor prognosis [93] . Various serum markers have been investigated for their utility in diagnosing and tracking progression and recurrence. Alkaline phosphatase (ALP) and lactose dehydrogenase (LDH) are useful serum biomarkers, with ALP carrying the most diagnostic value in OS [94, 95] . ALP has also been shown to correlate positively with tumor volume, which carries additional useful prognostic implications [94] [95] [96] . LDH has also been shown to correlate with tumor volume; however, the correlation is weaker than for ALP and is mainly a result of nonspecific metabolic demand [95] . [104] . Please refer to Table 1 for a list of test properties, including sensitivity, specificity, and a brief note on diagnostic application (as indicated by the study from which those numbers were derived). Note, however, that despite the promising aspects of these non-invasive techniques, a biopsy is always required to confirm the diagnosis [105] . As such, proper disease management mandates tissue collection with the correct identification of the specific histologic subtype [106] . While many subtypes exist and correlate specifically to corresponding chemotherapeutic responses [107] , the unifying histological feature is the presence of osteoid-producing malignant cells [105] .
Incisional or core needle biopsy is the final step in the diagnostic process [97] and the tumor is staged using the Musculoskeletal Tumor Society staging scheme [108] or the American Joint Commission on Cancer (AJCC) system. In the AJCC system, the tumor is described based on four important factors represented by letters [109] : T (primary tumor size), N (spread to regional lymph nodes), M (metastasis), and G (grade). Each letter is then assigned a particular number (e.g., T1) that describes the tumor's pathologic extent (T, N, and M) and histological appearance (G Telangiectatic OS is notable for its profuse vascularity and scant osteoid production, which often complicates tissue biopsy and radiographic identification, respectively [112] .
Telangiectatic OS also carries with it an anatomical predilection to the epiphyseal region of the bone. All high-grade OS should be considered micrometastatic at diagnosis and treated with surgery and systemic chemotherapy.
TREATMENT
The current standard for osteosarcoma treatment employs neoadjuvant chemotherapy, surgery, and then post-operative adjuvant chemotherapy. [145, 146] and mitogen-activated protein kinases [146, 147] have also recently been recognized as potential targets and their therapeutic significance is currently under investigation.
Over the past few decades, increasing evidence has suggested that platelets and other mesenchymal cells, notably the PDGFR-alpha-R for OS [148] , can assist tumor cell pathogenesis [149] . Indeed, Labelle et al. [150] showed that platelet-tumor cell interactions, mediated by activation of transforming growth factor (TGF)-beta/SMAD (small mothers against decapentaplegic) and nuclear factor (NF)-kappa-B, could promote metastasis by inducing an epithelial-mesenchymal-like transition. As such, Takagi et al. [151] was able to significantly inhibit platelet-induced OS cell proliferation by blocking Akt-mediated downstream signaling using sunitinib.
Likewise, sunitinib has since been shown to reduce tumor burden and lung metastasis in mice [152] ; however, the clinical significance of these initial data is yet to be determined. can be packaged within liposomes [160] and injected [161, 162] . This liposomal product (Mifamurtide) allows for particle ingestion by monocytes and macrophages and the subsequent activation of their cytotoxic function against tumor cells [163] . Tumor-associated macrophages, although mostly thought of as being pro-tumorigenic [164] , have been found to play a potentially significant role in preventing metastasis in high-grade OS [165] . In patients with no clinically detectable metastases and in those with resectable disease, the addition of
Mifamurtide to multi-agent chemotherapy has been shown to significantly increase event-free survival (EFS) and overall survival with a 29% reduction in the mortality rate at 8 years [166] .
The addition of Mifamurtide also improved the outcomes of patients who presented with metastases at the time of diagnosis [167] . A therapeutic synergism of MTP with zoledronic acid on primary tumor progression has also been suggested [168] . There have also been attempts to target immunotherapy directly to the lungs via the use of aerosols, which have the potential benefit of lowering systemic toxicity by being delivered directly to the site of action [169] . OS relapse most commonly occurs as pulmonary metastasis [105] , with patient survival often being below 30% [170, 171] and as low as 14%
[20] in these cases. Granulocyte-macrophage colony stimulating factor (GM-CSF), a molecule with multiple roles in immune regulation and phagocyte maturation [172] , was recently used in a phase II trial of post-relapse OS patients to investigate its effect on disease-free survival (DFS). However, despite the ability to reach adequately high doses with minimal side effects, no significant improvement in survival was seen [173] . While these results are disappointing, they may indicate that the immunomodulatory effects of GM-CSF alone were not enough to influence a tumorocidal environment. Unfortunately, there was no investigation of whether GM-CSF treatment resulted in any biologic effect on the lung tumor nodules. Therefore, it is hard to assess whether this therapy resulted in the desired effect in terms of activating an immune response in the lung. Thus, the possibility remains that the lack of therapeutic effect was secondary to the inability of GM-CSF to stimulate an immune response in the lung. [174, 175] and it is highly possible that further manipulation may be necessary to achieve an effective tumorocidal environment [176] [186] . Another in vitro study
showed that INF-gamma can enhance the ability of cd T cells to target and kill HOS and U2OS OS cell lines [187] .
As it is now widely accepted that tumors often promote suppression of the immune system in order to facilitate their pathogenesis [188] , many immunotherapies have shown promise by targeting immunoregulatory cell-surface markers. Programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are surface receptors involved in down-regulating the cytotoxic T cell response [189] [190] [191] and their blockade has been implicated in the treatment of a variety of cancers [192] . Interestingly, combined blockade of PD-L1 and CTLA-4 has been shown not only to completely eliminate metastatic osteosarcoma in murine models but also to induce immunity to further inoculation [193, 194] . 
CONCLUSIONS
